361 Capital’s Coherus Oncology CHRS Stock Holding History

361 Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-51,487	Closed	-$835K	–	317
2020 Q1	$835K	Sell	51,487 -12,205	-19%	-$225K	0.38%	90
2019 Q4	$1.15M	Sell	63,692 -70,586	-53%	-$1.3M	0.32%	195
2019 Q3	$2.72M	Sell	134,278 -3,061	-2%	-$61.2K	0.5%	52
2019 Q2	$3.04M	Buy	+137,339	New	+$2.39M	0.54%	29

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

361 Capital's CHRS Position: Q2 2020 in Review

361 Capital sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 51,487 shares — an estimated $835K sold.

361 Capital first reported a position in CHRS in Q2 2019 and held it in 4 quarters. The position peaked at $3.04M in Q2 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

361 Capital reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
361 Capital sold 51,487 Coherus Oncology shares in Q2 2020, an estimated $835K.
361 Capital first reported a position in Coherus Oncology in Q2 2019 and held it in 4 quarters.
361 Capital's Coherus Oncology position peaked at $3.04M in Q2 2019.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.